ERBB3 and colonic neoplasm: In metastatic CRC, patients with high amphiregulin and low HRG plasma levels have higher response rates to cetuximab-based therapies.[34] In BRAF-V600E mutant colon cancer stem cells (CSCs), HER3/Neuregulin-1β induces cellular proliferation and drug resistance to vemurafenib.[35]